Jonathan Rich Joins Luventix Advisory Board
Luventix, a leading innovator in Intelligent Disease Diagnostics, is pleased to announce that Jonathan Rich has joined its Advisory Board.
Jonathan Rich is an accomplished leader with extensive experience in capital markets, advisory services, and business strategy. As the CEO of Sophia Advisors, he has been instrumental in providing tailored consulting and advisory services to management teams, boards, and stakeholders of emerging growth companies. With over 30 years of experience across sell-side, buy-side, and issuer engagement, Jonathan's expertise in financial, operational, and governance considerations has been invaluable to his clients.
Beyond his professional achievements, Jonathan is deeply committed to philanthropy and community service. He serves on the boards of several nonprofit organizations, including Friends of Parkinson's Inc., Pajama Program, and Eleventh Hour Rescue, where he actively contributes to causes related to health, child welfare, and animal advocacy.
"We are honored to welcome Jonathan Rich to our Advisory Board," said George Holmes, CEO of Luventix. "His wealth of experience in financial advisory and strategic leadership will provide crucial insights as we continue to expand our presence and innovation in the diagnostics industry."
About Luventix:
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment, and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com.
Media Contact:
